LifeSciences BC > News > Industry News > 2014 > Biotechnology Focus Magazine – Sirona Biochem to license technology from Cincinnati Children’s Hospital Medical Center

Print Friendly, PDF & Email

B.C. Industry News

Biotechnology Focus Magazine – Sirona Biochem to license technology from Cincinnati Children’s Hospital Medical Center

January 20, 2014

Biotechnology Focus

BC-based cosmetic ingredient and drug discovery company Sirona Biochem Corp. has inked a license agreement with Cincinnati Children’s Hospital Medical Center for the formalization of a patented synthetic vernix technology.

Sirona Biochem plans to create an anti-aging skin care treatment that combines their patented cell preservation glycoprotein with the Cincinnati Children’s Hospital Medical Center technology. Sirona will lead the development, with support from Cincinnati Children’s, of the anti-aging cream incorporating the proprietary technologies of each organization. The resulting new anti-aging product will be patented with the goal of licensing the new technology to a global player in the cosmetic and consumer packaged good marketplace.

It is expected by both Sirona and Cincinnati Children’s that new patents and applications (cosmetic and therapeutic) for this combined technology may be discovered and the collaboration is structured to support the goal of future commercial revenue from multiple sources.

“We are proud to be working in partnership with Cincinnati Children’s Hospital Medical Center, a world leader in patient care and breakthrough research,” said Neil Belenkie, CEO of Sirona Biochem. “Our shared goal is to create an anti-aging skin treatment that presents unparalleled efficacy and commercial opportunity for the predicted $300 billion dollar anti-aging global market.”

“We are excited to formalize this agreement with Sirona Biochem and look forward to continuing to work together,” said Dr. Niki Robinson,  assistant vice president of Cincinnati Children’s Center for Technology Commercialization.